Alnylam Pharmaceuticals
ALNY
#1145
Rank
A$29.59 B
Marketcap
A$220.95
Share price
-3.17%
Change (1 day)
-67.47%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2026 (TTM): A$1.77 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are A$5.01 Billion. In 2025 the company made an earning of A$1.04 Billion, an increase over its 2024 earnings that were of -A$0.35 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) A$1.77 B70.7%
2025 A$1.04 B-403.41%
2024 -A$0.35 Billion-24.59%
2023 -A$0.46 Billion-67.84%
2022 -A$1.42 Billion36.93%
2021 -A$1.04 Billion-8.04%
2020 -A$1.13 Billion-15.66%
2019 -A$1.34 Billion12.23%
2018 -A$1.19 Billion62.91%
2017 -A$0.73 Billion17.78%
2016 -A$0.62 Billion43.44%
2015 -A$0.44 Billion60.69%
2014 -A$0.27 Billion98.2%
2013 -A$0.14 Billion
2011 -A$79.88 Million27.48%
2010 -A$62.66 Million-10.92%
2009 -A$70.34 Million95.77%
2008 -A$35.93 Million
2006 -A$57.56 Million-9.13%
2005 -A$63.35 Million34.74%
2004 -A$47.02 Million36.79%
2003 -A$34.37 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Novartis
NVS
A$18.42 B 935.08%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
A$10.43 B 486.21%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
A$7.52 B 322.94%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-A$0.2 Billion-110.72%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-A$69.11 Million-103.88%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-A$0.12 Billion-106.54%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
A$2.33 B 31.40%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
-A$0.24 Billion-113.06%๐Ÿ‡บ๐Ÿ‡ธ USA